Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for Brazilians, and the company’s current research on immunostimulants.
Before presenting the company, could you tell our readers what motivated you to shift from academic research towards a commercial venture?
"Orygen is an exciting hybrid between a commercial venture and an entrepreneurial, biotech start-up."
